Literature DB >> 318917

Idiopathic acquired sideroblastic anemia terminating in acute myelofibrosis: case report and review of leterature.

K Yeung, A A Trowbridge.   

Abstract

Acute myelofibrosis is a rare but distinct accelerated variant of agnogenic myeloid metaplasia that is characterized by marked anemia, peripheral blood myeloblastosis and normoblastosis, a lack of teardrop poikilocytosis, and prominent myelofibrosis. There is usually no palpable hepatosplenomegaly or lymph node enlargement. The clinical course is remarkable short. We describe a 63-year-old man who presented with idiopathic acquired sideroblastic anemia and subsequently developed acute myelofibrosis. Intensive polychemotherapy with vincristine, cytosine arabinoside, and prednisone and a later trial of oxymetholone therapy were ineffective. He died 134 days after the diagnosis of acute myelofibrosis was established. The 11 previously reported cases of acute myelofibrosis are reviewed, and the relationships of acute myelofibrosis to other myeloproliferative disorders and to idiopathic acquired sideroblastic anemia are discussed.

Entities:  

Mesh:

Year:  1977        PMID: 318917     DOI: 10.1002/1097-0142(197701)39:1<359::aid-cncr2820390155>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

Review 1.  Bone biopsy in haematological disorders.

Authors:  R Burkhardt; B Frisch; R Bartl
Journal:  J Clin Pathol       Date:  1982-03       Impact factor: 3.411

2.  Haematological features of primary myelodysplastic syndromes (PMDS) at initial presentation: a study of 118 cases.

Authors:  S K Juneja; M Imbert; H Jouault; J Y Scoazec; F Sigaux; C Sultan
Journal:  J Clin Pathol       Date:  1983-10       Impact factor: 3.411

3.  Idiopathic acquired sideroblastic anaemia transforming to acute myelosclerosis.

Authors:  A C Bested; G Cheng; P H Pinkerton; O Kassim; J S Senn
Journal:  J Clin Pathol       Date:  1984-09       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.